Cochrane · systematic review · CD009178
Pharmacotherapies for sleep disturbances in dementia
McCleery, J, Sharpley, AL · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
14
No studies
7
Included studies
NR
No studies 7 · 33.3%Ungraded 0 · 0%Very low 0 · 0%Low 8 · 38.1%Moderate 6 · 28.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsMelatonin compared to placebo for sleep disturbances in dementia
Population: sleep disturbances in dementia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total nocturnal sleep time Melatonin vs placebo | no estimate extracted | 2 studies · 184 participants | Low Downgraded: imprecision |
Consolidated sleep time Melatonin vs placebo | no estimate extracted | NR | No studies |
Number of nocturnal awakenings Melatonin vs placebo | no estimate extracted | 1 study · 33 participants | Low Downgraded: imprecision |
Reporting ≥ 1 adverse event Melatonin vs placebo | RR 1.07 [0.86, 1.33] | 1 study · 151 participants | Low Downgraded: imprecision |
Cognitive function Melatonin vs placebo | no estimate extracted | 2 studies · 162 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Quality of life Melatonin vs placebo | no estimate extracted | NR | No studies |
Carer burden Melatonin vs placebo | no estimate extracted | 1 study · 31 participants | Low Downgraded: imprecision |
Trazodone compared to placebo for sleep disturbances in dementia
Population: sleep disturbances in dementia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total nocturnal sleep time Trazodone vs placebo | no estimate extracted | 1 study · 30 participants | Low Downgraded: imprecision |
Consolidated nocturnal sleep time Trazodone vs placebo | no estimate extracted | NR | No studies |
Number of nocturnal awakenings Trazodone vs placebo | no estimate extracted | 1 study · 30 participants | Low Downgraded: imprecision |
Reporting ≥ 1 adverse event Trazodone vs placebo | RR 0.67 [0.23, 1.89] | 1 study · 30 participants | Low Downgraded: imprecision |
Cognitive function Trazodone vs placebo | no estimate extracted | 1 study · 30 participants | Moderate Downgraded: imprecision |
Quality of life Trazodone vs placebo | no estimate extracted | NR | No studies |
Carer burden, well‐being or quality of life Trazodone vs placebo | no estimate extracted | NR | No studies |
Orexin antagonists compared to placebo for sleep disturbances in dementia
Population: sleep disturbances in dementia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change from baseline in total nocturnal sleep time Orexin antagonists vs placebo | no estimate extracted | 1 study · 274 participants | Moderate Downgraded: imprecision |
Consolidated sleep time Orexin antagonists vs placebo | no estimate extracted | NR | No studies |
Change from baseline in ratio of number of nocturnal awakenings to total sleep time × 100 Orexin antagonists vs placebo | no estimate extracted | 1 study · 274 participants | Moderate Downgraded: imprecision |
Reporting ≥ 1 adverse event Orexin antagonists vs placebo | RR 1.29 [0.83, 1.99] | 2 studies · 323 participants | Moderate Downgraded: imprecision |
Change from baseline in cognitive function Orexin antagonists vs placebo | no estimate extracted | 1 study · 274 participants | Moderate Downgraded: imprecision |
Quality of life Orexin antagonists vs placebo | no estimate extracted | NR | No studies |
Change from baseline in carer distress Orexin antagonists vs placebo | no estimate extracted | 1 study · 274 participants | Moderate Downgraded: imprecision |